

## LY2157299

Catalog Number :7007224

RUO: For Research Use Only. Not for use in diagnostic procedures.

### Product Information

**Synonyms:** LY 2157299, LY-2157299, Galunisertib

**Chemical Name:** 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide

**Molecular Formula:** C<sub>22</sub>H<sub>19</sub>N<sub>5</sub>O

**Molecular Weight:** 369.4


**CAS Number:** 700874-72-2

**Purity:** ≥98%

**Applications:** FA

**Formulation:** Crystalline solid

**Storage:** Product should be kept at -20°C.



### Description

LY2157299 is a potent inhibitor of Transforming Growth factor-Beta Receptor I (TGF-BetaR). TGF-Beta1 is involved in the control of cell growth, proliferation, differentiation, and apoptosis. LY2157299 is reported to disrupt Smad-2 phosphorylation in Human Umbilical Vein Endothelial Cells (HUVEC) and inhibit the growth and migration of tumor cells.

### Preparation & Storage

Soluble in organic solvents such as ethanol or DMSO. DMSO up to 25mg/ml.

### References

- Bueno, L., de Alwis, D. P., Pitou, C., Yingling, J., Lahn, M., Glatt, S., Trocóniz, I. F. (2008). Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice.;*European journal of cancer*,;44(1), 142-150.
- Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., ... Slapak, C. A. (2015). Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.;*Drug design, development and therapy*,;9, 4479.
- Maier, A., Peille, A. L., Vuaroqueaux, V., Lahn, M. (2015). Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.;*Cellular Oncology*,;38(2), 131-144.
- Yingling, J. M., Shou, J., Xia, X., Chen, Y., Yan, L., Evans, W., ... Law, K. (2006). A small molecule inhibitor of TGFβ RI kinase potentiates VEGF dependent angiogenesis in vitro.;*Cancer Research*,;66(8 Supplement), 59-59.